First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial - Rimawi, Mothaffar; Ferrero, Jean-Marc; Haba-rodriguez, Juan de la; Poole, Christopher; Placido, Sabino De; Osborne, C. Kent; Hegg, Roberto; Easton, Valerie; Wohlfarth, Christine; Arpino, Grazia (Journal of clinical oncology, 2018)